Urokinase and Plasminogen Activator Inhibitor Type 1 in Pulmonary Adenocarcinoma

Cancer Research

Volumn 54, Issue 1, 1994, Pages 120-123

  Pedersen, Helle ^a   Grøndahl Hansen, Jan ^a   Francis, Dorte ^c   Østerlind, Kell ^b   Hansen, Heine Høi ^b   Danø, Keld ^a   Briinner, Nils ^a  

^a FINSEN LABORATORY   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER SURGERY; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0028144441     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Danø, K. Andreasen, P. A. Grøndahl-Hansen, J. Kristensen, P. Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res. 44: 139–266, 1985.
2. Blasi, R. Vassalli, J. D., and Danø, K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol. 104: 801–504, 1987.
3. Liotta, L. A., and Steeg, P. S. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327–336, 1991.
4. Pollanen, J. Stephens, R. W., and Vaheri, A. Directed plasminogen activation at the surface of normal and malignant cells. Adv. Cancer Res. 57: 273–328, 1991.
5. Petersen, L. C. Lund, L. R. Nielsen, L. S. Danø, K., and Skriver, L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J. Biol. Chem. 263: 11189–11195, 1988.
6. Ellis, V. Pyke, C. Eriksen, J. Solberg, H., and Danø, K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann. N. Y. Acad. Sci. 667: 13–31, 1992.
7. Andreasen, P. A. Georg, B. Lund, L. R. Riccio, A., and Stacey, S. N. Plasminogen activator inhibitors: hormonally regulated serpins. Mol. Cell. Endocrinol. 68: 1–19, 1990.
8. Murphy, G. Ward, R. Gavrilovic, J., and Atkinson, S. Physiological mechanisms for metalloproteinase activation. In: H. Birkedal-Hansen, Z. Werb, H. Welgus, and H. Van Wart (eds.), Matrix Metalloproteinases and Inhibitors, pp. 245–255. Stuttgart, Germany: Gustav Fischer Verlag, 1992.
9. Ossowski, L., and Reich, E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell, 35: 611–619, 1983.
10. Ossowski, L. Clunie, G. Masucci, M. T., and Blasi, F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol. 775: 1107–1112, 1991.
11. Skriver, L. Larsson, L. I. Kielberg, V. Nielsen, L. S. Andresen, P. B. Kristensen, P., and Danø, K. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J. Cell Biol. 99: 753–758, 1984.
12. Grøndahl-Hansen, J. Ralfkiaer, E. Kirkeby, L. T. Kristensen, P. Lund, L. R., and Danø, K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am. J. Pathol. 138: 111–117, 1991.
13. Pyke, C. Kristensen, P. Ralfkiaer, E. Grøndahl-Hansen, J. Eriksen, J. Blasi, R., and Danø, K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. 138: 1059–1067, 1991.
14. Pyke, C. Kristensen, P. Ralfkiasr, E. Eriksen, J., and Danø, K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 57: 4067–4071, 1991.
15. S0rensen, J. B., and Badsberg, J. H. Prognostic factors in resected stages I and II adenocarcinoma of the lung. J. Thorac. Cardiovasc. Surg. 99: 218–226, 1990.
16. Lipford, E. H. Ill, Eggleston, J. C. Lillemoe, K. D. Sears, D. L. Moore, G. W., and Baker, R. R. Prognostic factors in surgically resected limited-stage, non small cell carcinoma of the lung. Am. J. Surg. Pathol. 8: 357–365, 1984.
17. Mountain, C. R. Lukeman, J. M. Hammar, S. P. Chamberlain, D. W. Coulson, W R, Page, D. L. Victor, T. A., and Weiland, L. H. Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J. Surg. Oncol. 35: 147–156, 1987.
18. Quinlan, D. C. Davidson, A. G. Summers, C. L. Warden, H. E., and Doshi, H. M. Accumulation of p. 3 protein correlates with poor prognosis in human lung cancer. Cancer Res. 52: 4828–4831, 1992.
19. Horio, Y. Takahashi, T. Kuroishi, T. Hibi, K. Suyama, M. Niimi, T. Shimokata, K. Yamakawa, K. Nakamura, Y. Ueda, R. et al. Prognostic significance of p. 3 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 53: 1–1, 1993.
20. Slebos, R. J. Kibbelaar, R. E. Daleiso, O. Kooistra, A. Meijer, C. J. Wagenaar, S. S. Vanderschuren, R. G. van Zandwijk, N. Mooi, W. J. et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med. 323: 561–565, 1990.
21. Mitsudomi, T. Steinberg, S. M. Oie, H. K. Mulshine, J. L. Phelps, R. Viallet, J. Pass, H. Minna, J. D., and Gazdar, A. F. ras gene mutations in non-small-cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 57: 4999–5002, 1991.
22. Duffy, M. J. Reilly, D. O'Sullivan, C. O'Higgins, N. Fennelly, J. J., and Andreasen, P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 50: 6827–6829, 1990.
23. J¨anicke, R. Schmitt, M., and Graeff, H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemost. 17: 303–312, 1991.
24. Grøndahl-Hansen, J. Christensen, I. J. Rosenquist, C. Briinner, N. Mouridsen, H. T. Danø, K., and Blichert-Toft, M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53: 2513–2521, 1993.
25. Foekens, J. A. Schmitt, M. van Putten, W. L. J. Peters, H. A. Bontenbal, M. Janicke, R., and Klijn, J. G. M. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 52: 6101–6105, 1992.
26. Oka, T. Ishida, T. Nishino, T., and Sugimachi, K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res. 57: 3522–3525, 1991.
27. Camiolo, S. M. Suita, M. R., and Madeja, J. M. Improved medium for extraction of plasminogen activator from tissue. Prep. Biochem. 72: 297–305, 1982.
28. Rosenquist, C. Thorpe, S. M. Danø, K., and Grøndahl-Hansen, J. Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res. Treat. 28: 223–230, 1993.
29. Grøndahl-Hansen, J. Ralfkiasr, E. Nielsen, L. S. Kristensen, P. Frentz, G., and Danø, K. Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin. J. Invest. Dermatol, 88: 28–32, 1987.
30. Cox, D. R. Regression models and life tables (with discussion). J.R. Stat. Soc, 757: 187–220, 1972.
31. Ellis, V. Wun, T. C. Behrendt, N. R0nne, E., and Danø, K. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J. Biol. Chem. 265: 9904–9908, 1990.
32. Andreasen, P. A. Nielsen, L. S. Kristensen, P. Grøndahl-Hansen, J. Skriver, L., and Danø, K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J. Biol. Chem. 267: 7644–7651, 1986.
33. Kristensen, P. Pyke, C. Lund, L. R. Andreasen, P. A., and Danø, K. Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry, 93: 559–566, 1990.
34. Reilly, D. Christensen, L. Duch, M. Nolan, N. Duffy, M. J., and Andreasen, P. A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int. J. Cancer, 50: 208–214, 1992.
35. Cubellis, M. V. Wun, T. C., and Blasi, F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 9: 1079–1085, 1990.